Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon α-2a as first-line endocrine treatments in advanced breast cancer: Updated results of a phase II, prospective, randomised multicentre trial

Acta Biomedica de l'Ateneo Parmense

Volumn 78, Issue 3, 2007, Pages 204-209

  Chiesa, Matteo Dalla ^a,e   Passalacqua, Rodolfo ^a   Michiara, Maria ^b   Franciosi, Vittorio ^b   Di Costanzo, Francesco ^c   Bisagni, Giancarlo ^d   Camisa, Roberta ^b   Buti, Sebastiano ^a   Tomasello, Gianluca ^a   Cocconi, Giorgio ^b  

^a CREMONA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

^e Oncology Division   (Italy)

Author keywords

13 cis retinoic acid; Advanced breast cancer; Interferon 2a; Tamoxifen

Indexed keywords

ALPHA2A INTERFERON; ESTROGEN RECEPTOR; ISOTRETINOIN; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HOT FLUSH; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; METRORRHAGIA; MUCOSA INFLAMMATION; MUCOSAL DISEASE; MYALGIA; POSTMENOPAUSE; PROGNOSIS; SKIN TOXICITY; TREATMENT RESPONSE; VOMITING; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2A; ISOTRETINOIN; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; POSTMENOPAUSE; PROGNOSIS; PROSPECTIVE STUDIES; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 41749108460     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lacroix A, Lippman MF, et al. Binding of retinoids to human breast cancer cell lines and their effect on cell growth. J Clin Invest 1980; 65: 586-91.
2. Wetherall NT, Taylor CM, et al. The effects of retinoid treatment and antiestrogens on the growth of T 47 D human breast cancer cells. Eur J Cancer Clin Oncol 1986; 22: 53-9.
3. Sporn MB, Roberts AB, Wakefield LM, Glick AB. Growth factors and retinoids in suppression of neoplasia. Cancer Res 1990; 31: 463.
4. Cassidy J, Lippman M, Lacroix A, Pecks G. Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. Eur J Cancer Clin Oncol 1982; 18: 925-8.
5. Muss HB, Kempf RA, Martino S, et al. A phase II study of recombinant alfa interferon in patients with recurrent metastatic breast cancer. J Clin Oncol 1984; 2: 1012-6.
6. Barreras L, Vogel CL, Koch G, Marcus SG. Phase II trial of recombinant beta (IFN-beta) interferon in the treatment of metastatic breast cancer. Investigational New Drugs 1988; 2: 211-5.
7. Sherwin SA, Mayer D, Ochs JJ, et al. Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial. Ann Int Med 1983; 98: 598-602.
8. Muss HB, Caponera M, Zecan PJ, et al. Recombinant gamma interferon in advanced breast cancer: a phase II trial. Investigational New Drugs 1986; 4: 377-81.
9. Sarna GP, Figlin RA. Phase II trial of alfa-lymphoblastoid interferon given weekly as treatment of advanced breast cancer. Cancer Treat Rep 1985; 69: 547-9.
10. Bruntsch U, Groos G, Tigges FJ, et al. Lack of response in nine patients with breast cancer treated with fibroblast interferon. Cancer Chemother Pharmacol 1984; 13: 39-42.
11. Borden EC, Holland HF, Dao TL, et al. Leukocyte-derived interferon alpha in human breast cancer. Ann Intern Med; 97: 1-6.
12. Gutterman JU, Blumenschein GR, Alexanian R, et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Int Med 1980; 93: 399-406.
13. Pozzolt F, Otto AM, Trauschel LB, et al. Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. J Cancer Res Clin Oncol 1989; 115: 465-9.
14. Recchia F, Morgante A, Ercole C, et al. Differentiation induction and Tamoxifen therapy for stage IV breast cancer. Preliminary report of a phase II study. Proceed. ASCO 1990; 9: 50.
15. Di Blasio B, Dalla Chiesa M, Franciosi V, et al. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon a-2a as first-line endocrine treatments in advanced breast cancer: results of a phase III prospective randomised multicentric trial. Annals of Oncology 2002; 13, suppl. 3, abstr A56.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
17. Bonneterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus Tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18: 3748-57.
18. Nabholtz JM, Budzar A, Pollak W, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomised trial. J Clin Oncol 2000; 18: 2758-3767.
19. Milla-Santos A, Milla L, Rallo L, Solana V. Anastrozole vs. tamoxifen in hormonodependent advanced breast cancer: a phase II randomized trial. Breast Cancer Research Treatment 2000; 64: abstract 173.
20. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer group. J Clin Oncol 2001; 19: 2596-606.
21. th Annual San Antonio Breast Cancer Symposium 2001; 69: 211. Abstract 9.
22. Paridaens R, Dirix L, Lohrisch C, et al. Activity and safety of exemestane (E) as first-line hormonal therapy (HT) in metastatic breast cancer (MBC) patients (PTS): final results of an EORTC randomized phase II trial. Breast Cancer Research Treatment 2000; 64: Abstract 167.